1
|
Akgün E, Körner M, Gao F, Harkumar KG, Waser B, Reubi JC, Portoghese PS, Miller LJ. Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem 2009; 52:2138-47. [PMID: 19271701 PMCID: PMC2666544 DOI: 10.1021/jm801439x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Radiolabeled antagonists of specific peptide receptors identify a higher number of receptor binding sites than agonists and may thus be preferable for in vivo tumor targeting. In this study, two novel radioiodinated 1,4-benzodiazepines, (S)-1-(3-iodophenyl)-3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea (9) and (R)-1-(3-iodophenyl)-3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea (7), were developed. They were characterized in vitro as high affinity selective antagonists at cholecystokinin types 1 and 2 (CCK(1) and CCK(2)) receptors using receptor binding, calcium mobilization, and internalization studies. Their binding to human tumor tissues was assessed with in vitro receptor autoradiography and compared with an established peptidic CCK agonist radioligand. The (125)I-labeled CCK(1) receptor-selective compound 9 often revealed a substantially higher amount of CCK(1) receptor binding sites in tumors than the agonist (125)I-CCK. Conversely, the radioiodinated CCK(2) receptor-selective compound 7 showed generally weaker tumor binding than (125)I-CCK. In conclusion, compound 9 is an excellent radioiodinated nonpeptidic antagonist ligand for direct and selective labeling of CCK(1) receptors in vitro. Moreover, it represents a suitable candidate to test antagonist binding to CCK(1) receptor-expressing tumors in vivo.
Collapse
Affiliation(s)
- Eyup Akgün
- University of Minnesota, Department of Medicinal Chemistry, College of Pharmacy, Minneapolis, MN 55455
| | - Meike Körner
- Mayo Clinic, Department of Molecular Pharmacology and Experimental Therapeutics, Scottsdale, AZ 85259
| | - Fan Gao
- Mayo Clinic, Department of Molecular Pharmacology and Experimental Therapeutics, Scottsdale, AZ 85259
| | - Kaleeckal G. Harkumar
- Mayo Clinic, Department of Molecular Pharmacology and Experimental Therapeutics, Scottsdale, AZ 85259
| | - Beatrice Waser
- Institute of Pathology of the University of Berne, Division of Cell Biology and Experimental Cancer Research, 3010 Berne, Switzerland
| | - Jean Claude Reubi
- Institute of Pathology of the University of Berne, Division of Cell Biology and Experimental Cancer Research, 3010 Berne, Switzerland
| | - Philip S. Portoghese
- University of Minnesota, Department of Medicinal Chemistry, College of Pharmacy, Minneapolis, MN 55455
| | - Laurence J. Miller
- Mayo Clinic, Department of Molecular Pharmacology and Experimental Therapeutics, Scottsdale, AZ 85259
| |
Collapse
|
2
|
Abstract
Cholecystokinin and gastrin receptors (CCK1R and CCK2R) are G protein-coupled receptors that have been the subject of intensive research in the last 10 years with corresponding advances in the understanding of their functioning and physiology. In this review, we first describe general properties of the receptors, such as the different signaling pathways used to exert short- and long-term effects and the structural data that explain their binding properties, activation, and regulation. We then focus on peripheral cholecystokinin receptors by describing their tissue distribution and physiological actions. Finally, pathophysiological peripheral actions of cholecystokinin receptors and their relevance in clinical disorders are reviewed.
Collapse
Affiliation(s)
- Marlène Dufresne
- Institut National de la Santé et de la Recherche Médicale U. 531, Institut Louis Bugnard, Centre Hospitalier Universitaire Rangueil, France
| | | | | |
Collapse
|
3
|
Morton MF, Pyati J, Dai H, Li L, Moreno V, Shankley NP. Molecular cloning, expression and pharmacological characterization of the canine cholecystokinin 1 receptor. Br J Pharmacol 2006; 145:374-84. [PMID: 15765098 PMCID: PMC1576148 DOI: 10.1038/sj.bjp.0706196] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
1 The full-length, canine cholecystokinin 1 (CCK1) receptor was cloned from gallbladder tissue using RT-PCR with a combination of primers designed to interact with conserved regions of the human and rat CCK1 receptor, which also shared homology with the canine genomic sequence. 2 Analysis of the sequence of the canine CCK1 receptor revealed a 1287 base pair product, which encoded a 429 amino-acid protein. This protein was 89% identical to the human and 85% identical to the rat CCK1 receptor. 3 The canine CCK1 receptor was expressed in CHO-K cells for pharmacological characterization. In competition studies, using [(125)I]BH-CCK-8S as radioligand, the affinity values estimated for CCK receptor-selective compounds were not significantly different between the canine and human CCK1 receptors (pK(I)+/-s.e.m. at canine CCK1 receptor; L-364,718=8.82+/-0.08, L-365,260=6.61+/-0.05, YF476=7.91+/-0.15, YM022=8.28+/-0.06 and dexloxiglumide=7.53+/-0.11). Furthermore, the selectivity of these compounds between canine CCK1 and CCK2 receptors was consistent with the selectivity between the human CCK1 and CCK2 receptors. 4 Two additional forms of the canine CCK1 receptor were identified during the cloning procedure. These had three (variant #1) and six (variant #2) amino-acid differences from the wild-type canine CCK1 receptor. Variant #1 bound [(125)I]BH-CCK-8S and displayed an identical pharmacological profile to the wild-type receptor using the ligands described above. No significant binding was measured with variant #2. 5 In conclusion, we have cloned and pharmacologically characterized the canine CCK1 receptor. The data obtained will facilitate the interpretation of numerous pharmacological experiments that have been performed using canine tissue to elucidate the actions of CCK and gastrin.
Collapse
Affiliation(s)
- Magda Francesca Morton
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C, 3210 Merryfield Row, San Diego, CA 92121, USA.
| | | | | | | | | | | |
Collapse
|
4
|
Martín-Martínez M, Marty A, Jourdan M, Escrieut C, Archer E, González-Muñiz R, García-López MT, Maigret B, Herranz R, Fourmy D. Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor. J Med Chem 2005; 48:4842-50. [PMID: 16033264 DOI: 10.1021/jm0501127] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A rational combination of site-directed mutagenesis studies, structure-activity relationships, and dynamic-based docking of pyridopyrimidine-derived CCK1R antagonists into a refined three-dimensional model of the CCK1R allowed us to identify the receptor residues and the ligand functional groups implicated in the molecular recognition process. Our results provided unambiguous evidence that the binding site of these antagonists is overlapping that of the C-terminal tetrapeptide of CCK. In particular, Asn333 and Arg336 residues of the CCK1R are essential for high-affinity binding of these ligands. Moreover, the 2-aryl group in the pyridopyrimidine derivatives shares the same binding pocket as the C-terminal Phe side chain of CCK. Our [pyridopyrimidine.CCK1R] complex model is consistent with previous suggestions concerning the molecular basis that governs functional activity and provides useful considerations about the high CCK1 versus CCK2 selectivity of our derivatives and could contribute to fine-tune the rational design of new molecules with optimized properties.
Collapse
|
5
|
Archer-Lahlou E, Tikhonova I, Escrieut C, Dufresne M, Seva C, Pradayrol L, Moroder L, Maigret B, Fourmy D. Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor. J Med Chem 2005; 48:180-91. [PMID: 15634012 DOI: 10.1021/jm049886y] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The Cholecystokinin-1 receptor (CCK1R) mediates actions of CCK in areas of the central nervous system and of the gut. It is a potential target to treat a number of diseases. As for all G-protein-coupled receptors, docking of ligands into modeled CCK1R binding site should greatly help to understand intrinsic mechanisms of activation. Here, we describe the procedure we used to progressively build a structural model for the CCK1R, to integrated, and on the basis of site-directed mutagenesis data on its binding site. Reliability of the CCK1R model was confirmed by interaction networks that involved conserved and functionally crucial motifs in G-protein-coupled receptors, such as Glu/Asp-Arg-Tyr and Asn-Pro-Xaa-Xaa-Tyr motifs. In addition, the 3-D structure of CCK1R-bound CCK resembled that determined by NMR in a lipid environment. The derived computational model was also used for revealing binding modes of several nonpeptide ligands and for rationalizing ligand structure-activity relationships known from experiments. Our findings indeed support that our "validated CCK1R model" could be used to study the intrinsic mechanism of CCK1R activation and design new ligands.
Collapse
Affiliation(s)
- Elodie Archer-Lahlou
- INSERM U 531, Institut Louis Bugnard, CHU Rangueil, Bat. L3, 31403 Toulouse Cedex 4, France
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Mangiapia G, Accardo A, Lo Celso F, Tesauro D, Morelli G, Radulescu A, Paduano L. Mixed Micelles Composed of Peptides and Gadolinium Complexes as Tumor-Specific Contrast Agents in MRI: A SANS Study. J Phys Chem B 2004. [DOI: 10.1021/jp048466h] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Gaetano Mangiapia
- Dipartimento di Chimica, Università degli Studi di Napoli “Federico II”, Via Cinthia, 80126 Napoli, Italy, Dipartimento di Chimica Biologica, Centro Interuniversitario per la Ricerca sui Peptidi Bioattivi (CIRPeB), Università degli Studi di Napoli “Federico II”, Via Mezzocannone 6, 80134 Napoli, Italy, Dipartimento di Chimica Fisica, Università degli Studi di Palermo, Viale delle Scienze, Parco d'Orleans II, 90128 Palermo, Italy, and Institute for Solid State Research, Research Center Jülich GmbH, Jülich
| | - Antonella Accardo
- Dipartimento di Chimica, Università degli Studi di Napoli “Federico II”, Via Cinthia, 80126 Napoli, Italy, Dipartimento di Chimica Biologica, Centro Interuniversitario per la Ricerca sui Peptidi Bioattivi (CIRPeB), Università degli Studi di Napoli “Federico II”, Via Mezzocannone 6, 80134 Napoli, Italy, Dipartimento di Chimica Fisica, Università degli Studi di Palermo, Viale delle Scienze, Parco d'Orleans II, 90128 Palermo, Italy, and Institute for Solid State Research, Research Center Jülich GmbH, Jülich
| | - Fabrizio Lo Celso
- Dipartimento di Chimica, Università degli Studi di Napoli “Federico II”, Via Cinthia, 80126 Napoli, Italy, Dipartimento di Chimica Biologica, Centro Interuniversitario per la Ricerca sui Peptidi Bioattivi (CIRPeB), Università degli Studi di Napoli “Federico II”, Via Mezzocannone 6, 80134 Napoli, Italy, Dipartimento di Chimica Fisica, Università degli Studi di Palermo, Viale delle Scienze, Parco d'Orleans II, 90128 Palermo, Italy, and Institute for Solid State Research, Research Center Jülich GmbH, Jülich
| | - Diego Tesauro
- Dipartimento di Chimica, Università degli Studi di Napoli “Federico II”, Via Cinthia, 80126 Napoli, Italy, Dipartimento di Chimica Biologica, Centro Interuniversitario per la Ricerca sui Peptidi Bioattivi (CIRPeB), Università degli Studi di Napoli “Federico II”, Via Mezzocannone 6, 80134 Napoli, Italy, Dipartimento di Chimica Fisica, Università degli Studi di Palermo, Viale delle Scienze, Parco d'Orleans II, 90128 Palermo, Italy, and Institute for Solid State Research, Research Center Jülich GmbH, Jülich
| | - Giancarlo Morelli
- Dipartimento di Chimica, Università degli Studi di Napoli “Federico II”, Via Cinthia, 80126 Napoli, Italy, Dipartimento di Chimica Biologica, Centro Interuniversitario per la Ricerca sui Peptidi Bioattivi (CIRPeB), Università degli Studi di Napoli “Federico II”, Via Mezzocannone 6, 80134 Napoli, Italy, Dipartimento di Chimica Fisica, Università degli Studi di Palermo, Viale delle Scienze, Parco d'Orleans II, 90128 Palermo, Italy, and Institute for Solid State Research, Research Center Jülich GmbH, Jülich
| | - Aurel Radulescu
- Dipartimento di Chimica, Università degli Studi di Napoli “Federico II”, Via Cinthia, 80126 Napoli, Italy, Dipartimento di Chimica Biologica, Centro Interuniversitario per la Ricerca sui Peptidi Bioattivi (CIRPeB), Università degli Studi di Napoli “Federico II”, Via Mezzocannone 6, 80134 Napoli, Italy, Dipartimento di Chimica Fisica, Università degli Studi di Palermo, Viale delle Scienze, Parco d'Orleans II, 90128 Palermo, Italy, and Institute for Solid State Research, Research Center Jülich GmbH, Jülich
| | - Luigi Paduano
- Dipartimento di Chimica, Università degli Studi di Napoli “Federico II”, Via Cinthia, 80126 Napoli, Italy, Dipartimento di Chimica Biologica, Centro Interuniversitario per la Ricerca sui Peptidi Bioattivi (CIRPeB), Università degli Studi di Napoli “Federico II”, Via Mezzocannone 6, 80134 Napoli, Italy, Dipartimento di Chimica Fisica, Università degli Studi di Palermo, Viale delle Scienze, Parco d'Orleans II, 90128 Palermo, Italy, and Institute for Solid State Research, Research Center Jülich GmbH, Jülich
| |
Collapse
|
7
|
Morton MF, Harper EA, Tavares IA, Shankley NP. Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle. Br J Pharmacol 2002; 136:873-82. [PMID: 12110612 PMCID: PMC1573423 DOI: 10.1038/sj.bjp.0704794] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
1. The pharmacology of the cholecystokinin CCK(1) receptors endogenously expressed in human gallbladder and human ascending colon smooth muscle tissue was compared using radioligand binding assays. 2. Saturation analysis of the interaction between the radiolabelled, selective CCK(1)-receptor antagonist, [(3)H]-L-364,718, and enriched gastrointestinal tissue membranes suggested the presence of multiple binding sites in human colon but not human gallbladder. 3. Competition studies, using a range of structurally diverse, CCK-receptor selective ligands provided further evidence for CCK(1) receptor heterogeneity in human colon tissue (n(H) values significantly less than unity for SR27897=0.77+/-0.07, 2-NAP=0.73+/-0.03, YM220=0.70+/-0.09 and PD-134,308=0.83+/-0.01). Moreover, the competition data for SR27897, 2-NAP and YM220 were consistent with the interaction of these compounds at two binding sites. In contrast, in the human gallbladder assay, a single binding site model provided a good fit of the competition curve data obtained with all the CCK receptor selective compounds. 4. The data obtained are consistent with the presence of a single CCK(1) receptor binding site in the gallbladder but not in the colon. A two-site analysis of the colon data, indicated that one of the two sites was indistinguishable from that characterized in the gallbladder. The molecular basis of the apparent receptor heterogeneity in the colon remains to be established.
Collapse
Affiliation(s)
- M F Morton
- Academic Department of Surgery, GKT Schools of Medicine and Dentistry, King's College, London.
| | | | | | | |
Collapse
|
8
|
Albrizio S, Carotenuto A, Fattorusso C, Moroder L, Picone D, Temussi PA, D'Ursi A. Environmental mimic of receptor interaction: conformational analysis of CCK-15 in solution. J Med Chem 2002; 45:762-9. [PMID: 11831889 DOI: 10.1021/jm0109457] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
CCK-15, a peptide derived from the 115-membered CCK preprohormone, was the object of a comparative conformational analysis by NMR spectroscopy and molecular modeling methods. NMR data in several solvents demonstrate that the propensity of the peptide to fold into a helical conformation is intrinsic, not merely a consequence of the interaction with phosphatidylcholine micelles or with a putative receptor, as suggested by a previous study on CCK-8 (Pellegrini, M.; Mierke, D. Biochemistry 1999, 38, 14775-14783.). The prevailing CCK-15 conformer in a mixture 1,1,1,3,3,3-hexafluoroacetone/water reveals that the residues common to CCK-15 and CCK-8 assume very similar conformations. Our CCK-15 structure is consistent with the model of receptor interaction proposed by Pellegrini and Mierke and discloses possible novel interactions that involve a larger area of the putative receptor. The consensus structure between CCK-15 and CCK-8 shows a good superposition of the side chains of residues 12-14 with crucial moieties of two non-peptidic CCK-A antagonists.
Collapse
Affiliation(s)
- Stefania Albrizio
- Dipartimento di Scienze Farmaceutiche, Università di Salerno, via Ponte Don Melillo 11 c, I-84084 Fisciano, Italy
| | | | | | | | | | | | | |
Collapse
|
9
|
Kisfalvi K, Rácz G, Zsirka-Klein A, Pelosini I, Scarpignato C, Varga G. Different affinity states of CCK(1) receptors on pancreatic acini and gastric smooth muscle in the rat. JOURNAL OF PHYSIOLOGY, PARIS 2001; 95:391-8. [PMID: 11595465 DOI: 10.1016/s0928-4257(01)00053-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
It has recently been shown that--after chronic cholecystokinin (CCK) treatment--an adaptation of pancreatic secretory but not gastric motor function does occur. Recent studies indicate that the CCK(1)-receptor exists in two (i.e. high and low) affinity states, which could be distinguished by the CCK-analogue JMV-180. CCK occupancy of high and low affinity sites is thought to be related to the initiation of different intracellular events and consequent biological responses. Affinity states of CCK(1)-receptors on pancreas and gastrointestinal (GI) smooth muscle could be different and this can offer an explanation for the different effects of CCK on pancreatic and gastric growth. We therefore studied the affinity states of CCK(1)-receptors on isolated rat pancreatic acini and gastric smooth muscle preparations. When acini were incubated with increasing concentrations of CCK-8, a biphasic (i.e. stimulation followed by inhibition) effect on amylase release was observed. JMV-180 caused only stimulation of enzyme release and combined JMV-180 and CCK stimulation (at submaximal doses) resulted in an additive secretory response. CCK-8 induced contractions of pyloric, antral and fundic muscle in a concentration-dependent manner. The response was monophasic, reaching a plateau. JMV-180 had only a very weak effect on these preparations. On the contrary, it inhibited CCK-induced contractions in a competitive manner, the concentration-response curve to CCK being shifted to the right by the CCK analogue. Our data suggest that the affinity states of CCK(1)-receptors on rat pancreatic and gastric tissue are different. On pancreatic acini CCK(1)-receptors exist in both high- and low-affinity states whose occupation is followed by the sequence of intracellular events leading to growth. In contrast, occupation of low affinity receptors (the only ones present in the GI smooth muscle) does not lead to cell proliferation. This difference therefore explains the different adaptive response of the pancreas and the stomach to chronic CCK administration. Furthermore, different affinity states of CCK(1)-receptors may mediate different functions of the digestive tract.
Collapse
Affiliation(s)
- K Kisfalvi
- Institute of Experimental Medicine, Hungarian Academy of Sciences, 1450 Budapest, PO Box 67, Budapest, Hungary
| | | | | | | | | | | |
Collapse
|
10
|
Bisello A, Behar V, Greenberg Z, Suva LJ, Rosenblatt M, Chorev M. Development of a photoreactive parathyroid hormone antagonist to probe antagonist-receptor bimolecular interaction. THE JOURNAL OF PEPTIDE RESEARCH : OFFICIAL JOURNAL OF THE AMERICAN PEPTIDE SOCIETY 1999; 54:120-8. [PMID: 10461746 DOI: 10.1034/j.1399-3011.1999.00096.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Parathyroid hormone (PTH) and PTH-related protein (PTHrP) exert their calciotropic activities by binding to a specific seven-transmembrane-helix-containing G protein-coupled receptor mainly located in bone and kidney cells. In order to map in detail the nature of hormone-receptor interaction, we are employing 'photoaffinity scanning' of the bimolecular interface. To this end, we have developed photoreactive benzophenone (BP)-containing PTH analogs which can be specifically and efficiently cross-linked to the human (h) PTH/PTHrP receptor. In this report, we describe the photocross-linking of a BP-containing PTH antagonist, [Nle8,18,D-2-Nal12,Lys13(epsilon-BP),2-Nal23,Tyr34]bPT H(7-34)NH2 (ANT) to the recombinant hPTH/PTHrP receptor stably expressed in human embryonic kidney cells (HEK-293, clone C-21). This photoreactive antagonist has high affinity for the hPTH/PTHrP receptor and inhibits agonist-induced cyclase activity and intracellular calcium release. The photo-induced cross-linking of the radioiodinated antagonist (125I-ANT) to the recombinant hPTH/PTHrP receptor followed by SDS-PAGE analysis reveals a single radiolabeled band of approximately 85kDa, similar to that observed after cross-linking of a radioiodinated BP-containing agonist. The formation of this covalent 125I-ANT - hPTH/PTHrP receptor conjugate is competed dose-dependently by a variety of unlabelled PTH- and PTHrP-derived agonists and antagonists. This is the first report of a specific and efficient photocross-linking of a radioiodinated PTH antagonist to the hPTH/PTHrP receptor. Therefore, it provides the opportunity to study directly the nature of the bimolecular interaction of PTH antagonist with the hPTH/PTHrP receptor.
Collapse
Affiliation(s)
- A Bisello
- Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
| | | | | | | | | | | |
Collapse
|
11
|
Gigoux V, Escrieut C, Fehrentz JA, Poirot S, Maigret B, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy D. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin. J Biol Chem 1999; 274:20457-64. [PMID: 10400673 DOI: 10.1074/jbc.274.29.20457] [Citation(s) in RCA: 71] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The cholecystokinin-A receptor (CCK-AR) is a G protein-coupled receptor that mediates important central and peripheral cholecystokinin actions. Residues of the CCK-AR binding site that interact with the C-terminal part of CCK that is endowed with biological activity are still unknown. Here we report on the identification of Arg-336 and Asn-333 of CCK-AR, which interact with the Asp-8 carboxylate and the C-terminal amide of CCK-9, respectively. Identification of the two amino acids was achieved by dynamics-based docking of CCK in a refined three-dimensional model of CCK-AR using, as constraints, previous results that demonstrated that Trp-39/Gln-40 and Met-195/Arg-197 interact with the N terminus and the sulfated tyrosine of CCK, respectively. Arg-336-Asp-8 and Asn-333-amide interactions were pharmacologically assessed by mutational exchange of Arg-336 and Asn-333 in the receptor or reciprocal elimination of the partner chemical functions in CCK. This study also allowed us to demonstrate that (i) the identified interactions are crucial for stabilizing the high affinity phospholipase C-coupled state of the CCK-AR.CCK complex, (ii) Arg-336 and Asn-333 are directly involved in interactions with nonpeptide antagonists SR-27,897 and L-364,718, and (iii) Arg-336 but not Asn-333 is directly involved in the binding of the peptide antagonist JMV 179 and the peptide partial agonist JMV 180. These data will be used to obtain an integrated dynamic view of the molecular processes that link agonist binding to receptor activation.
Collapse
Affiliation(s)
- V Gigoux
- INSERM U151, Institut Louis Bugnard, Centre Hospitalier Universitaire Rangueil, Bat. L3, 31403 Toulouse Cedex 4, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Roettger BF, Pinon DI, Burghardt TP, Miller LJ. Regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist. THE AMERICAN JOURNAL OF PHYSIOLOGY 1999; 276:C539-47. [PMID: 10069980 DOI: 10.1152/ajpcell.1999.276.3.c539] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Partial agonists are effective tools for advancing development of highly selective drugs and providing insights into molecular regulation of cellular functions. Here, we explore the impact of a partial agonist on key aspects of cholecystokinin (CCK) receptor regulation, its lateral mobility and cellular trafficking, in native pancreatic acinar cells and Chinese hamster ovary cells expressing CCK receptor (CHO-CCKR). We developed and characterized a novel fluorescent partial agonist, rhodamine-Gly-[(Nle28, 31)CCK-26-32]-phenethyl ester, that binds specifically and with high affinity to CCK receptors. Such analogs are fully efficacious pancreatic acinar cell secretagogues without supramaximal inhibition that mobilize intracellular calcium with little or no increase in phospholipase C (PLC) activity. Despite minimal phosphorylation of CCK receptors in response to this partial agonist, receptor trafficking was the same as that observed with full agonist (CCK). This included normal internalization via clathrin-dependent endocytosis in CHO-CCKR cells and insulation on the surface of pancreatic acinar cells. Also, as with CCK-occupied receptor, fluorescence recovery after photobleaching of partial agonist-occupied receptor on the acinar cell surface demonstrated a marked temperature-dependent slowing of its rate of diffusion. This was similarly associated with resistance to acid-induced dissociation of ligand. Thus some key molecular regulatory mechanisms for CCK receptor internalization and insulation may be initiated by cellular signaling cascades that are not dependent on PLC activation or receptor phosphorylation.
Collapse
Affiliation(s)
- B F Roettger
- Center for Basic Research in Digestive Diseases and Department of Biochemistry and Molecular Biology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
| | | | | | | |
Collapse
|
13
|
Schaschke N, Fiori S, Weyher E, Escrieut C, Fourmy D, Müller G, Moroder L. Cyclodextrin as Carrier of Peptide Hormones. Conformational and Biological Properties of β-Cyclodextrin/Gastrin Constructs. J Am Chem Soc 1998. [DOI: 10.1021/ja973852g] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Norbert Schaschke
- Contribution from the Max-Planck-Institut für Biochemie, 82152 Martinsried, Germany, INSERM U152, CHU Rangueil, 31054 Toulouse Cedex, France, and Bayer AG, MD-IM-FA, Q18, 51368 Leverkusen, Germany
| | - Stella Fiori
- Contribution from the Max-Planck-Institut für Biochemie, 82152 Martinsried, Germany, INSERM U152, CHU Rangueil, 31054 Toulouse Cedex, France, and Bayer AG, MD-IM-FA, Q18, 51368 Leverkusen, Germany
| | - Elisabeth Weyher
- Contribution from the Max-Planck-Institut für Biochemie, 82152 Martinsried, Germany, INSERM U152, CHU Rangueil, 31054 Toulouse Cedex, France, and Bayer AG, MD-IM-FA, Q18, 51368 Leverkusen, Germany
| | - Chantal Escrieut
- Contribution from the Max-Planck-Institut für Biochemie, 82152 Martinsried, Germany, INSERM U152, CHU Rangueil, 31054 Toulouse Cedex, France, and Bayer AG, MD-IM-FA, Q18, 51368 Leverkusen, Germany
| | - Daniel Fourmy
- Contribution from the Max-Planck-Institut für Biochemie, 82152 Martinsried, Germany, INSERM U152, CHU Rangueil, 31054 Toulouse Cedex, France, and Bayer AG, MD-IM-FA, Q18, 51368 Leverkusen, Germany
| | - Gerhard Müller
- Contribution from the Max-Planck-Institut für Biochemie, 82152 Martinsried, Germany, INSERM U152, CHU Rangueil, 31054 Toulouse Cedex, France, and Bayer AG, MD-IM-FA, Q18, 51368 Leverkusen, Germany
| | - Luis Moroder
- Contribution from the Max-Planck-Institut für Biochemie, 82152 Martinsried, Germany, INSERM U152, CHU Rangueil, 31054 Toulouse Cedex, France, and Bayer AG, MD-IM-FA, Q18, 51368 Leverkusen, Germany
| |
Collapse
|
14
|
Niida T, Nagahama T, Oumi T, Ukena K, Morishita F, Furukawa Y, Matsushima O, Tsutsui K, Ohtani M, Muneoka Y, Fujita T, Kawano T, Minakata H, Nomoto K. Characterization of binding of the annelidan myoactive peptides, GGNG peptides, to tissues of the earthworm,Eisenia foetida. ACTA ACUST UNITED AC 1997. [DOI: 10.1002/(sici)1097-010x(19971215)279:6<562::aid-jez4>3.0.co;2-l] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
15
|
Philippe C, Lhoste EF, Dufresne M, Moroder L, Corring T, Fourmy D. Pharmacological and biochemical evidence for the simultaneous expression of CCKB/gastrin and CCKA receptors in the pig pancreas. Br J Pharmacol 1997; 120:447-54. [PMID: 9031748 PMCID: PMC1564491 DOI: 10.1038/sj.bjp.0700940] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
1. In the pig, the secretory response of the pancreas is not inhibited by the antagonist MK329 suggesting that cholecystokininA (CCKA) receptors are not involved. 2. Membranes were isolated from the pancreas of 6 Large White pigs to characterize their CCK receptors. 3. The binding of [125I]-BH-[Thr, Nle]CCK-9 was dependent on pH, maximal after a 90 min incubation period, saturable and reversible. Saturation analysis of the binding demonstrated a single class of high affinity sites (Kd = 0.22 +/- 0.02 nM) and a binding capacity, Bmax = 110.64 +/- 12.50 fmol mg-1 protein. 4. Competition binding by agonists and antagonists of CCKA and CCKB/gastrin receptors demonstrated the presence of two distinct binding components, sites presenting a high affinity for [Thr, Nle]CCK-9, gastrin, PD 135158, L-365, 260 and a low affinity for MK329, SR 27897, and sites presenting a high affinity for [Thr, Nle]CCK-9, MK329, SR 27897 and a low affinity for gastrin, PD 135158, L-365,260. 5. These pharmacological data demonstrate the presence of both CCKA and CCKB/gastrin receptors in the pig pancreas, the latter being predominant. 6. Two distinct membrane proteins (50 and 85-100 kDa, respectively) display pharmacological features of CCKB/gastrin and CCKA receptors. 7. In pigs, as in calves and humans, CCKB/gastrin receptors are predominant in the pancreas.
Collapse
Affiliation(s)
- C Philippe
- Laboratoire d'Ecologie et de Physiologie du Système Digestif, INRA, Jouy-en-Josas, France
| | | | | | | | | | | |
Collapse
|
16
|
Grant G, Henderson LT, Edwards JE, Ewan EC, Bardocz S, Pusztai A. Kidney bean and soybean lectins cause enzyme secretion by pancreatic acini in vitro. Life Sci 1997; 60:1589-95. [PMID: 9126881 DOI: 10.1016/s0024-3205(97)00125-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The responses of pancreas acini from Hooded-Lister rats to kidney bean E2L2 lectin or soybean agglutinin have been studied in vitro. Both lectins induced secretion of alpha-amylase from acini in a dose dependent manner. However, the concentrations of lectin required to cause enzyme secretion were approximately 14-fold higher than that necessary with CCK-8. In addition, the responsiveness of pancreas acini to lectins in vitro was significantly altered by the age and sex of the rats from which the acini were derived.
Collapse
Affiliation(s)
- G Grant
- Rowett Research Institute, Aberdeen, Scotland, UK.
| | | | | | | | | | | |
Collapse
|
17
|
Singh P, Owlia A, Espeijo R, Dai B. Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors. J Biol Chem 1995; 270:8429-38. [PMID: 7721737 DOI: 10.1074/jbc.270.15.8429] [Citation(s) in RCA: 84] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
We have reported previously mitogenic effects of gastrin on several immortalized and neoplastic cell lines, including Swiss 3T3 fibroblasts. Receptor subtypes, cholecystokinin (CCK)-A and CCK-B, for a closely related peptide, cholecystokinin, were recently cloned. These studies were undertaken to investigate if CCK-A- and CCK-B receptors were perhaps mediating the mitogenic effects of gastrin on Swiss 3T3 cells. Receptor antagonists that inhibit the biological effects and binding of peptides to the CCK-A (L-364,718 (L18)) and CCK-B (L-365,260 (L60)) receptors were ineffective toward inhibiting the binding and proliferative effects of gastrin on Swiss 3T3 cells. Radiolabeled L18 and L60 demonstrated no binding to the cells, indicating that CCK-A and CCK-B receptors may be absent on Swiss 3T3 cells. Radiolabeled CCK-8, gastrin, L18, and L60, on the other hand, demonstrated specific binding to a pancreatic cancer cell line (AR42J cells) (used as a positive control). In cross-linking studies the molecular mass of the major band of gastrin receptors (GR) on Swiss 3T3 cells was determined to be approximately 45 kDa. The mitogenic potency of 0.1-1.0 nM gastrin-like peptides on Swiss 3T3 cells was in the order of G1-17 > or = G1-17-Gly > G5-17 > or = G5-17-Gly > G2-17 > CCK-8-Gly > or = G1-17-Lys > or = CCK-8. The relative binding affinity of the peptides (based on the dose-dependent inhibition of binding of 125I-G1-17 to Swiss 3T3 cells) was similar to the relative mitogenic potency of the peptides as given above. Furthermore, G1-17-Gly was equally effective as G1-17 in displacing the binding of 125I-G1-17 to the 45-kDa GR from the Swiss 3T3 cells. Based on these studies it became evident that the novel gastrin preferring GR, expressed by Swiss 3T3 cells, binds and mediates the mitogenic effects of not only the mature (amidated) forms of gastrin-like peptides but also binds and mediates the mitogenic effects of glycine-extended forms of gastrin-like peptides. Possible mRNA expression of CCK-A and CCK-B receptor subtypes by gastrin-responsive rodent intestinal and fibroblast cell lines (Swiss 3T3, IEC-6, CA) was measured by the methods of Northern blot analysis and reverse transcriptase-polymerase chain reaction. mRNA from rat pancreas, AR42J cells, and rat antrum served as positive controls.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
MESH Headings
- 3T3 Cells
- Amides/metabolism
- Animals
- Cell Division/drug effects
- Cell Line
- Gastrins/metabolism
- Gastrins/pharmacology
- Mice
- Protein Binding
- Protein Processing, Post-Translational
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Rats
- Receptor, Cholecystokinin A
- Receptor, Cholecystokinin B
- Receptors, Cholecystokinin/antagonists & inhibitors
- Receptors, Cholecystokinin/genetics
- Receptors, Cholecystokinin/metabolism
- Receptors, Cholecystokinin/physiology
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- P Singh
- Department of Anatomy and Neurosciences, University of Texas Medical Branch, Galveston 77555, USA
| | | | | | | |
Collapse
|
18
|
Hadjiivanova C, Petkov VV, Kehayov R, Martinez J. Behavioural effects of two cholecystokinin analogues: JMV 236 and JMV 179. Neuropeptides 1994; 27:163-7. [PMID: 7816187 DOI: 10.1016/0143-4179(94)90066-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The behavioural effects of two cholecystokinin analogues Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2 (JMV 236), a potent CCK agonist, and Boc-Tyr(SO3H)-Nle-Gly-DTrp-Nle-Asp-2-Phenylethylester (JMV 179), a CCK antagonist were studied. JMV 236 (3.125, 12.5 and 50 micrograms/kg i.p.) dose-dependently decreased the exploratory activity of rats, the effect being significant for horizontal activity (ambulation) at doses of 12.5 and 50 micrograms/kg and for vertical activity (rearing) at a dose of 50 micrograms/kg. JMV 179 (3.125, 12.5 and 50 micrograms/kg i.p.) did not change the horizontal activity but dose-dependently decreased the vertical activity, the effect being significant at a dose of 50 micrograms/kg. JMV 236 administered immediately after training significantly facilitated short-term memory in passive avoidance situation but only tended to increase the mean latency upon retention testing on the 7th day. JMV 179 tended to increase the latency of the passive avoidance response upon retention testing at the 24th hour but not on the 7th day after training.
Collapse
Affiliation(s)
- C Hadjiivanova
- Department of Experimental Pharmacology, Bulgarian Academy of Sciences, Sofia
| | | | | | | |
Collapse
|
19
|
Yule DI, Williams JA. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor. Peptides 1994; 15:1045-51. [PMID: 7527529 DOI: 10.1016/0196-9781(94)90069-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The ability of CCKA antagonists to inhibit full and partial CCK agonists of the rat pancreatic acinar cell CCKA receptor has been studied. When isolated rat pancreatic acini were superfused with CCK-8 (10 pM-1 nM) or CCK-4 (1 microM), an increase in [Ca2+]i signal was initiated. Concurrent superfusion of either L-364,718 (0.1 microM) or lorglumide (10 microM), chemically distinct, specific, potent antagonists of the CCKA receptor, resulted in a rapid inhibition of the [Ca2+]i signal initiated by all concentrations of CCK-8. In contrast, Ca2+ oscillations, initiated by JMV-180 (25 nM-1 microM), a partial agonist analogue of CCK-8, were essentially unaffected by concurrent superfusion of either L-364,718 or lorglumide. When JMV-179, an analogue of JMV-180 that exhibits characteristics of a pure antagonist, was superfused concurrently with either CCK-8 or JMV-180, Ca2+ oscillations were inhibited, even in the presence of 0.1 microM L-364,718. In a similar fashion, amylase secretion stimulated by CCK-8 was markedly attenuated by L-364,718, lorglumide, and JMV-179, whereas secretion stimulated by JMV-180 was only inhibited by JMV-179. A model is proposed to reconcile this data, based on the assumption that JMV-180 and CCK-8 interact with discrete sites on the CCKA receptor, which are differentially affected by the binding of antagonists. This model may also explain how a single receptor may transduce multiple signals in response to different agonists.
Collapse
Affiliation(s)
- D I Yule
- Department of Physiology, University of Michigan, Ann Arbor 48109
| | | |
Collapse
|
20
|
Silvente-Poirot S, Dufresne M, Vaysse N, Fourmy D. The peripheral cholecystokinin receptors. EUROPEAN JOURNAL OF BIOCHEMISTRY 1993; 215:513-29. [PMID: 8354258 DOI: 10.1111/j.1432-1033.1993.tb18061.x] [Citation(s) in RCA: 102] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- S Silvente-Poirot
- Institut Louis Bugnard, Institut National de la Santé et de la Recherche Médicale, U 151, Centre Hospitalier Universitaire de Rangueil, Toulouse, France
| | | | | | | |
Collapse
|